BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Nov 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-11-13

Reporting Person: Sheridan William P (Senior VP - CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-13	Common Stock	S	64310	$4.72	Disposed	23855	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person and represents approximately 6 percent of the reporting person's pre-sale vested and unvested holdings.

F2: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.65 to $4.78. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.